Replies to post #83521 on Biotech Values

[DewDiligence]

MNTA:

You're assuming no one else will ever be able to launch a generic lovenox. What makes you think Teva is the type of company to give up? If Sanofi is going to lose a massive market share, why wouldn't they launch an AG?

???

The calculation in question is for the best-case scenario, and the assumptions you're referring to are the definition of the best case.